Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Treasury Shares (2022 - 2025)

Lyra Therapeutics (LYRA) has disclosed Treasury Shares for 4 consecutive years, with $58882.0 as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares fell 93.21% to $58882.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $58882.0, a 93.21% decrease, with the full-year FY2024 number at $42865.0, down 59.19% from a year prior.
  • Treasury Shares was $58882.0 for Q3 2025 at Lyra Therapeutics, down from $85804.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $4.7 million in Q1 2025 to a low of $28212.0 in Q4 2022.
  • A 4-year average of $581525.7 and a median of $105048.0 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 588.08% in 2023, then crashed 93.21% in 2025.
  • Lyra Therapeutics' Treasury Shares stood at $28212.0 in 2022, then skyrocketed by 272.35% to $105048.0 in 2023, then tumbled by 59.19% to $42865.0 in 2024, then soared by 37.37% to $58882.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Treasury Shares are $58882.0 (Q3 2025), $85804.0 (Q2 2025), and $4.7 million (Q1 2025).